This article is more than 5 years old. Information may no longer be current.
Otsuka Pharmaceutical Company to be presented with Corporate Innovator Award
Click Here to Manage Email Alerts
The Otsuka Pharmaceutical Company Ltd. will be presented with the 2019 Corporate Innovator Award from the National Kidney Foundation at the 2019 Spring Clinical Meetings held in Boston.
According to a press release, Otsuka’s Jynarque (tolvaptan) was the first treatment shown to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
“Otsuka is honored to be recognized by the National Kidney Foundation as a recipient of the Corporate Innovator Award,” Louis Allesandrine, vice president of oncology and nephrology sales and marketing for the company, said in a press release. “Since the FDA approval of Jynarque 1 year ago, many people living with ADPKD in the U.S. have received this treatment. Otsuka continues to make significant investments in our nephrology research and development and is committed to meeting the long-term unmet needs of people living with chronic kidney disease.”
The Corporate Innovator Award was established by the NKF to recognize companies in nephrology that address an unmet medical need or improve an existing practice, therapeutic or technology.
“The Corporate Innovator Award recognizes Otsuka’s significant contribution to improving the lives of people with ADPKD, and we congratulate them on this achievement,” Kevin Longino, CEO of the NKF and a kidney transplant patient, said in the release.
Reference:
www.kidney.org/news/nkf-honors-otsuka-pharmaceutical-company-ltd-scm19-corporate-innovator-award